Literature DB >> 28800863

Targeting PI3K/AKT pathway in triple-negative breast cancer.

Suzette Delaloge1, Louise DeForceville2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28800863     DOI： 10.1016/S1470-2045(17)30514-4

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  19 in total

1.  miR-4461 inhibits the progression of Gallbladder carcinoma via regulating EGFR/AKT signaling.

Authors:  Xingzhou Yan; Pinghua Yang; Hu Liu; Yongyang Zhao; Zhixiong Wu; Baohua Zhang
Journal:  Cell Cycle       Date:  2022-02-23       Impact factor: 5.173

Review 2.  Triple-negative breast cancer: A run-through of features, classification and current therapies.

Authors:  Meghana Manjunath; Bibha Choudhary
Journal:  Oncol Lett       Date:  2021-05-05       Impact factor: 2.967

3.  MiR-125 inhibited cervical cancer progression by regulating VEGF and PI3K/AKT signaling pathway.

Authors:  Ke Fu; Ling Zhang; Rui Liu; Qi Shi; Xue Li; Min Wang
Journal:  World J Surg Oncol       Date:  2020-05-30       Impact factor: 2.754

Review 4.  Novel therapeutic avenues in triple-negative breast cancer: PI3K/AKT inhibition, androgen receptor blockade, and beyond.

Authors:  Jack J Chan; Tira J Y Tan; Rebecca A Dent
Journal:  Ther Adv Med Oncol       Date:  2019-10-09       Impact factor: 8.168

5.  Boosting immune surveillance by low-dose PI3K inhibitor facilitates early intervention of breast cancer.

Authors:  Jinyang Wang; Yuan Zhang; Yi Xiao; Xiangliang Yuan; Ping Li; Xiao Wang; Yimin Duan; Victoria L Seewaldt; Dihua Yu
Journal:  Am J Cancer Res       Date:  2021-05-15       Impact factor: 6.166

6.  Pancreatic cancer intrinsic PI3Kα activity accelerates metastasis and rewires macrophage component.

Authors:  Benoit Thibault; Fernanda Ramos-Delgado; Elvire Pons-Tostivint; Nicole Therville; Celia Cintas; Silvia Arcucci; Stephanie Cassant-Sourdy; Gabriela Reyes-Castellanos; Marie Tosolini; Amelie V Villard; Coralie Cayron; Romain Baer; Justine Bertrand-Michel; Delphine Pagan; Dina Ferreira Da Mota; Hongkai Yan; Chiara Falcomatà; Fabrice Muscari; Barbara Bournet; Jean-Pierre Delord; Ezra Aksoy; Alice Carrier; Pierre Cordelier; Dieter Saur; Celine Basset; Julie Guillermet-Guibert
Journal:  EMBO Mol Med       Date:  2021-05-25       Impact factor: 12.137

7.  He-Jie-Shen-Shi Decoction as an Adjuvant Therapy on Severe Coronavirus Disease 2019: A Retrospective Cohort and Potential Mechanistic Study.

Authors:  Haibo Hu; Kun Wang; Li Wang; Yanjun Du; Juan Chen; Yongchun Li; Chuanbo Fan; Ning Li; Ying Sun; Shenghao Tu; Xuechao Lu; Zhaoshan Zhou; Huantian Cui
Journal:  Front Pharmacol       Date:  2021-06-18       Impact factor: 5.810

8.  Overexpression of CLEC3A promotes tumor progression and poor prognosis in breast invasive ductal cancer.

Authors:  Jun Ni; Yun Peng; Fu-Lan Yang; Xun Xi; Xing-Wei Huang; Chun He
Journal:  Onco Targets Ther       Date:  2018-06-04       Impact factor: 4.147

9.  A cytoplasmic long noncoding RNA LINC00470 as a new AKT activator to mediate glioblastoma cell autophagy.

Authors:  Changhong Liu; Yan Zhang; Xiaoling She; Li Fan; Peiyao Li; Jianbo Feng; Haijuan Fu; Qing Liu; Qiang Liu; Chunhua Zhao; Yingnan Sun; Minghua Wu
Journal:  J Hematol Oncol       Date:  2018-06-04       Impact factor: 17.388

10.  MiR-1287-5p inhibits triple negative breast cancer growth by interaction with phosphoinositide 3-kinase CB, thereby sensitizing cells for PI3Kinase inhibitors.

Authors:  Daniela Schwarzenbacher; Christiane Klec; Barbara Pasculli; Stefanie Cerk; Beate Rinner; Michael Karbiener; Cristina Ivan; Raffaela Barbano; Hui Ling; Annika Wulf-Goldenberg; Stefanie Stanzer; Gabriel Rinnerthaler; Herbert Stoeger; Thomas Bauernhofer; Johannes Haybaeck; Gerald Hoefler; Stephan Wenzel Jahn; Paola Parrella; George Adrian Calin; Martin Pichler
Journal:  Breast Cancer Res       Date:  2019-02-01       Impact factor: 6.466
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.